Human Umbilical Cord blood monocytes, rescue brain cells from hypoxic-ischemic injury:

Finally I found publication about CD14 cells in cord blood from Duke!

here Duke study about CD14 +

Cd14 in cord blood

they found potential not in perepheric blood !!!so not all cd14 are equal :

« Gene expression microarray analysis demonstrated that compared to PB-CD14 monocytes, CB-CD14 monocytes over-expressed several secreted proteins with potential to protect neurons. Differential expression of five candidate effector molecules, chitinase 3-like protein-1, inhibin-A, interleukin-10, matrix metalloproteinase-9 and thrombospondin-1, were confirmed by western blotting, and immunofluorescence. These findings suggest that CD14 monocytes are a critical cell-type when treating HI with CB-MNC. »

« intravenously injected CB-MNC products [55] do not need to reach the brain in order to promote repair of stroke or other HI brain injury. Instead, cell products

reaching the lungs or spleen may induce endogenous cells to produce soluble factors or activated

cells that go to the brain and mediate repair [56-58]. Future studies investigating the

biodistribution of CB monocytes will determine the most effective route and dose for


In summary, monocytes in CB, but not PB, protect brain neurons from death and reduce glial

activation following HI insult in an in vitro OGD model. Soluble factors released from CB

monocytes contribute to this protection. We have identified secreted proteins enriched in CBCD14+ monocytes compared to PB monocytes that may play a role in neuroprotection and repair.

This work enables future detailed study of the mechanism of neuroprotection and development

of mechanism-based release assays for CB products, and formulation of new strategies for using

CB monocytes as therapeutic agents in treatment of HI-induced brain injuries. »

LOW-LEVEL LIGHT THERAPY (LLLT) or photobiomodulation.

Lideur mondiale dans étude de LLLT:

Michael R Hamblin Ph.D.

Associate Professor

Department of Dermatology

Harvard Medical School

BAR 414

Wellman Center for Photomedicine

Massachusetts General Hospital

40 Blossom Street

Boston MA 02114


Member of Affiliated Faculty of Harvard-MIT Division of Health Sciences and


Tel 617-726-6182

Fax 617-726-6643


“Low level laser (light) therapy (LLLT) also known as photobiomodulation (PBM) therapy has been practiced for almost fifty years, and hundreds of positive clinical trials and thousands of laboratory studies have been published. Despite these impressive accomplishments LLLT has still not reached the stage of acceptance by mainstream medicine. The reasons for this were discussed at a recent Optical Society of America (OSA) Incubator meeting in Washington DC in 2014. Uncertainty about mechanisms was highlighted, and this paper will describe the current thinking. To drive LLLT towards mainstream medicine, we need better guidelines with standardized protocols and consistent parameters. Studies should be published in higher impact scientific and medical journals. Companies should avoid false promises and deceptive marketing, and physicians should receive a clearly defined return on investment with insurance reimbursement.”




He adviced me to use this model: